Breaking News

WuXi Biologics Licenses GLS-010 to Arcus Biosciences

WuXi Biologics will be the exclusive manufacturer for GLS-010 in the licensed territories

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi Biologics and its Chinese partner Harbin Gloria Pharmaceuticals, entered an agreement to license the anti-PD-1 antibody GLS-010 to Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of cancer immunotherapies.    Gloria contracted WuXi Biologics to discover and develop GLS-010, a novel anti-PD-1 antibody, using Ligand’s transgenic rat platform OmniRat. GLS-010 is currently being evaluated in cancer patients in Phase I studies in China. Arcus ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters